Quick Answer
KALA BIO, Inc. reported Research And Development Expense of $18.35 million for the year ending 2020.
- KALA BIO, Inc. showed a decrease of -32.7% in Research And Development Expense from 2019 to 2020.
- This data is from KALA BIO, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2021.
- XBRL data for this metric is available from 2015 to 2020 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: $5.95 million | Q3 2016: $8.26 million | Q1 2017: $8.04 million | Q2 2017: $8.07 million | Q3 2017: $7.02 million | Q1 2018: $5.66 million | Q2 2018: $7.37 million | Q3 2018: $7.03 million | Q1 2019: $6.96 million | Q2 2019: $7.11 million | Q3 2019: $7.07 million | Q1 2020: $5.43 million | Q2 2020: $6.05 million | Q3 2020: $3.47 million | Q1 2021: $3.13 million | Q2 2021: $3.09 million | Q3 2021: $2.88 million | Q1 2022: $4.47 million | Q2 2022: $4.47 million | Q3 2022: $5.39 million | Q1 2023: $4.04 million | Q2 2023: $4.28 million | Q3 2023: $5.55 million | Q1 2024: $6.35 million | Q2 2024: $5.32 million | Q3 2024: $5.17 million | Q1 2025: $6.06 million | Q2 2025: $6.23 million | Q3 2025: $6.13 million.
- Over the full 6 years of available data (2015 to 2020), KALA BIO, Inc.'s Research And Development Expense has grown by 61.2%.
- Historical annual values: Fiscal year 2020: $18.35 million | Fiscal year 2019: $27.28 million | Fiscal year 2018: $29.29 million | Fiscal year 2017: $29.01 million | Fiscal year 2016: $25.03 million | Fiscal year 2015: $11.38 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: